A jury in Marshall, Texas, awarded Seagen Inc SGEN $41.82 million from Daiichi Sankyo Co DSNKY over claims that Daiichi and AstraZeneca plc's AZN breast-cancer drug Enhertu violates Seagen's patent rights.
- The jury found that Daiichi willfully infringed a patent owned by Seagen that covers technology for delivering chemotherapy drugs to cancer cells.
- Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo, said in a statement, "Daiichi Sankyo disagrees with the jury verdict, is committed to defending its rights, and will explore options with respect to the jury verdict, including post-trial motions and an appeal."
- Seagen said it was pleased with the verdict and would request additional royalties on future sales of Enhertu in the U.S. until the patent expires in November 2024.
- Seagen filed the lawsuit in the U.S. District Court for the Eastern District of Texas in 2020, claiming Enhertu works in the same way as its patent related to antibody-drug conjugates, which use antibodies to target cancer cells with chemotherapy drugs.
- Price Action: SGEN shares closed 2.74% lower at $151.84 on Friday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.